Abstract
The use of Botulinum Toxin is increasingly being extended in different conditions refractory to other treatments.
Thus, it is being used in dystonias, trigeminal neuralgia, migraines, headaches and alterations of the temporomandibular joint.
OBJECTIVES
Primary: To assess the improvement of night rest in the treatment with botulinum toxin type A in chronic Migraine. Trigeminal neuralgia (regardless of the affected branch) and involvement of the temporomandibular joint and/or Bruxism, after therapeutic failure maintained over time. Over more than two years of previous oral or topical drug therapies.
Secondary: To assess the effectiveness of the dose used and its average duration over time.
METHODS: 283 patients of both sexes, aged between 85 and 43 years, were included. The patients studied were separated by sex. Group A: over 80 years old. Group B: between 65 and 79 years old and Group C: under 64 years old.
25 IU of botulinum toxin type A were administered for trigeminal neuralgia, severe temporomandibular joint (TMJ) pain, migraines and headaches. , refractory for two years or more to medical treatments
RESULTS: In all groups, with doses of 25 IU in a single dose, there was a significant improvement in the rest, from the injection, until the six months of control, especially in the group C, in trigeminal neuralgia. It was not significant in the other conditions and/or age groups
CONCLUSIONS: In all groups the effectiveness was greater in trigeminal neuralgia at the established doses P<0.5 and more in the lower group age (C) with more than 6 months of improvement in the condition. In the rest of the pathologies treated, the results at the established doses are very similar to those of the referenced studies. Its use can be effective at doses of 25 IU.